James Brugarolas, Director, Kidney Cancer Program; Sherry Wigley Crow Endowed Chair in Cancer Research; Professor, Internal Medicine/ Hematology-Oncology, Cancer Biology, Genetics, Development and Disease

Financial relationships

  • Attribution:
    Self
    Type of financial relationship:
    Professional Services
    Ineligible company:
    Consultant
    Topic:
    Arrowhead Pharmaceuticals
    Date added:
    Date updated:
    07/01/2024
  • Attribution:
    Self
    Type of financial relationship:
    Professional Services
    Ineligible company:
    Consultant
    Topic:
    Exelixis, Inc.
    Date added:
    Date updated:
    07/01/2024
  • Attribution:
    Self
    Type of financial relationship:
    Professional Services
    Ineligible company:
    Consultant
    Topic:
    Eisai
    Date added:
    12/02/2021
    Date updated:
    07/01/2024
  • Attribution:
    Self
    Type of financial relationship:
    Professional Services
    Ineligible company:
    Consultant
    Topic:
    Johnson & Johnson
    Date added:
    12/02/2021
    Date updated:
    07/01/2024
  • Attribution:
    Self
    Type of financial relationship:
    Professional Services
    Ineligible company:
    Consultant
    Topic:
    Calithera
    Date added:
    12/02/2021
    Date updated:
    07/01/2024
Return to 156 Renal Cell Carcinoma Multimodality Conference: (020722)

 

**Disclaimer**

This Continuing Medical Education (CME) Learning Management System, Ethos, includes individuals designated as 'faculty' for CME purposes. Please note that the term 'faculty' refers solely to their role as a contributor/planner within a CME activity and does not imply any formal affiliation with UT Southwestern Medical Center (UTSW). The display of names and credentials is intended for educational purposes only and does not necessarily indicate a professional or academic relationship with UTSW. Participants are encouraged to verify the affiliations and credentials of faculty members independently if further clarification is needed.